Cutaneous drug reactions, a ransom to be paid in the quest for health;Les toxidermies iatrogènes, une rançon de la quête de la santé

Revue Medicale de Liege

Volumn 56, Issue 8, 2001, Pages 583-591

  Fumal, I ^a   Sriha, B ^a   Paquet, P ^a   Pierard Franchimont C ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adverse effect; Drug; Toxic epidermal necrolysis

Indexed keywords

AMPICILLIN; ANDROGEN; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMINE; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOSPORIN; DIPHENHYDRAMINE; EPHEDRINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; LITHIUM; PREDNISONE; PYRIDOXINE; TERBINAFINE; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL FEATURE; DRUG ERUPTION; HISTOLOGY; HUMAN; PATHOGENESIS; PROGNOSIS; SKIN TOXICITY;

DRUG ERUPTIONS; HUMANS;

EID: 0034840781     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Adverse drug reaction reporting in Europe: Some problems of comparison
2. Epidemiology of drug-induced severe skin reactions
3. Place of excipients in drug related allergy
4. Les médicaments responsables de nécrolyse épidermique toxique (syndrome de Lyell)
5. Toxidermie sévère polymorphe induite par le losartan
6. Drug-induced cutaneous reactions: A report from the Boston collaborative drug surveillance program on 15438 consecutive inpatients, 1975 to 1982
7. Cutaneous drug reactions: Clinical types and causative agents
8. Drug-induced psoriasis. Recognition and management
9. Cutaneous pathobiology mediated by chemotherapy
10. Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
11. Immunological physiopathology of cutaneous adverse drug reactions
12. Physiopathologie des toxidermies
13. Immunologic mechanisms of cutaneous drug reactions
14. Activation of drug-specific CD4+ and CD8+ cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine
15. Role of delayed cellular hypersensitivity and adhesion molecules in morbiliform rashes induced by amoxicillin
16. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced by antibiotics
17. Mechanisms of drug reactions: The metabolic track
18. Temporary skin reactions to penicillins during the acute stage of infectious mononucleosis
19. Cutaneous disease and drug reactions in HIV infection
20. Erythema multiforme and toxic epidermal necrolysis. A comparative study
21. Variétés histologiques des toxidermies médicamenteuses
22. Etude de l'expression des molécules médiant l'apoptose dans les toxidermies
23. Immediate hypersensitivity reactions to beta-lactam antibiotics
24. Acute generalized exanthematous pustulosis. Analysis of 63 cases
25. Acute generalized exanthematous pustulosis
26. Leukocytoclastic vasculitis caused by drug additives
27. Fixed drug eruptions: 77 Cases from 1981 to 1985
28. Fixed eruptions. Incidence, recognition, and avoidance
29. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis
30. Toxic epidermal necrolysis: Clinical findings and prognosis factors in 87 patients
31. Toxic epidermal necrolysis (Lyell syndrome)
32. La nécrolyse épidermique toxique: Du diagnostic au traitement
33. Pathogénie de la nécrolyse épidermique toxique (syndrome de Lyell)
34. Toxic epidermal necrolysis following clindamycin treatment
35. Eruptive speckled melanocytic nevi following drug-induced toxic epidermal necrolysis
36. Long-term corneal involvement following drug-induced toxic epidermal necrolysis (Lyell's disease)
37. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
38. Comparative pathobiology of drug induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction
39. Inhibition of toxic epidermal necrolysis by blocade of CD95 with human intravenous immunoglobulin
40. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins
41. Epidermal calprotectin in drug-induced toxic epidermal necrolysis
42. Macrophages and tumor necrosis factor-alpha in toxic epidermal necrolysis
43. Soluble fractions of tumor necrosis factor-a, interleukin 6 and of their receptors in toxic epidermal necrolysis. A comparison with second-degree burns
44. Gelatinases in drug-induced toxic epidermal necrolysis
45. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis
46. Regulatory function of factor XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. A hypothesis
47. Pharmacologic and immunochemical mechanisms of drug hypersensitivity
48. Drug hypersensitivity syndrome
49. Les pseudolymphomes cutanés
50. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with eosinophilia and systemic symptoms: DRESS)
51. Pourquoi faut-il traiter une onychomycose avec patience et persévérance? Comment contourner les éhecs thérapeutiques?
52. The use of skin testing in the investigation of cutaneous adverse drug reactions
53. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France
54. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?